An estriol (E3) test measures an estrogen produced in large amounts during pregnancy through cooperation between the fetus and placenta. Maternal serum unconjugated estriol is one component of the second-trimester triple or quadruple screening test, where it contributes to a probability estimate for certain chromosome conditions and open neural tube defects. It is not interpreted as a stand-alone “placenta health” score. A low value can occur with incorrect pregnancy dating, fetal chromosome conditions, placental dysfunction, fetal adrenal or steroid-synthesis disorders, or a pregnancy that is not progressing normally. Most low results do not establish a diagnosis and require confirmation with ultrasound, review of gestational age, and discussion of cell-free DNA screening or diagnostic testing. Estriol rises across pregnancy, so gestational-age-specific multiples of the median are more useful than a universal concentration range. Outside pregnancy, estriol is low and is rarely used to evaluate general estrogen status.
- Estriol is produced during pregnancy by the fetal-placental unit and rises as gestation advances.
- Unconjugated estriol is interpreted within a triple or quadruple screening risk calculation, not alone.
- Low E3 can reflect dating error, chromosome conditions, fetal steroid disorders, or placental dysfunction.
- An abnormal screen estimates risk and does not diagnose a fetal condition.
- Ultrasound and screening or diagnostic options should be reviewed with obstetric or genetic specialists.
- Bleeding, severe pain, reduced fetal movement, or signs of preeclampsia require urgent clinical assessment.
Table of Contents
- What the estriol Test Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- What High estriol Results Can Mean
- What Low estriol Results Can Mean
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the estriol Test Measures
The fetal adrenal glands produce steroid precursors that travel to the fetal liver and placenta. The placenta converts these precursors into estriol, which then enters maternal blood and urine. This shared pathway means E3 depends on fetal, placental, and maternal processes.
The form used in second-trimester serum screening is unconjugated estriol, commonly abbreviated uE3. The laboratory combines uE3 with alpha-fetoprotein, hCG, and sometimes inhibin A, then adjusts for gestational age and maternal factors to calculate risk.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
Estriol is different from estradiol, the dominant estrogen before menopause, and estrone, which becomes more prominent after menopause. Measuring total estrogen or estradiol cannot substitute for the uE3 component of prenatal screening.
A general estrogen levels test explains how E1, E2, and E3 differ across life stages.
Why the Test Is Ordered
E3 is most often measured as part of prenatal serum screening rather than ordered alone.
- Second-trimester triple or quadruple screening for fetal chromosome conditions and open neural tube defects.
- Follow-up of a very low uE3 result that may indicate a rare fetal steroid disorder.
- Selected high-risk pregnancy evaluation when a specialist uses serial hormone information.
- Research or specialized assessment of placental and fetal steroid metabolism.
- Rare evaluation of estrogen exposure outside pregnancy, where other estrogens are usually preferred.
Current prenatal screening choices include cell-free DNA screening, serum screening, ultrasound, and diagnostic procedures such as chorionic villus sampling or amniocentesis. The appropriate pathway depends on gestational age, prior results, ultrasound findings, personal values, and access. Screening tests estimate probability; diagnostic tests examine fetal genetic material.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
A broader estrogen levels test helps distinguish pregnancy estriol from E1 and E2 testing.
Preparation, Timing, and the Testing Process
Second-trimester serum screening is performed within a defined gestational window set by the program, commonly around 15–22 weeks, with narrower windows preferred by some laboratories.
- Confirm gestational age and how it was dated, ideally with an accurate ultrasound.
- Provide maternal age, weight, diabetes status, smoking status, race or ethnicity fields used by the laboratory, and number of fetuses.
- Report donor-egg pregnancy, IVF dating, and any vanishing twin because these can affect risk calculations.
- Bring prior screening and ultrasound results so the new result is not interpreted in isolation.
- Ask whether the test is screening or diagnostic and what follow-up options are available.
No special fasting is usually required. A dating error of even one or two weeks can change the expected median and therefore the multiple-of-the-median value. Twin and higher-order pregnancies require different calculations and may have different screening performance.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
E3 concentrations increase substantially through pregnancy. Prenatal programs usually convert the measured value to a multiple of the median (MoM) for the exact gestational age and adjust it for maternal and pregnancy factors.
| Report element | Meaning | Why it matters |
|---|---|---|
| Raw uE3 concentration | Measured serum amount | Cannot be compared across gestational weeks directly |
| MoM | Value divided by the expected median | Allows gestational-age comparison |
| Adjusted MoM | MoM corrected for maternal/pregnancy factors | Used in the screening algorithm |
| Combined risk | Probability based on all markers and history | Determines whether further counseling is offered |
| Screen-positive/negative | Program-specific risk threshold | Does not equal diagnosis or guarantee |
There is no single normal E3 number for all pregnancies. Even a low MoM has several possible explanations, and cutoffs differ among screening programs. The combined risk calculation is more meaningful than the isolated marker.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
Estriol should not be confused with the estradiol test, which serves different fertility and menopause purposes.
What High estriol Results Can Mean
High E3 is usually less specific than a low result and often reflects gestational age, multiple pregnancy, or normal placental-fetal steroid production.
- Pregnancy farther along than initially estimated.
- Twins or higher-order multiple pregnancy.
- Normal individual variation.
- Maternal or fetal factors incorporated into the screening algorithm.
- Laboratory or data-entry differences.
- Rarely, unusual placental or fetal steroid patterns.
A high isolated uE3 is not generally used to diagnose placental overactivity or a fetal disorder. Its contribution is evaluated within the full screening pattern. Ultrasound dating and anatomy findings usually provide more actionable information.
Prenatal screening algorithms are designed around combinations. For example, a marker pattern associated with one chromosome condition may differ from the pattern associated with an open neural tube defect. Reading only E3 can therefore produce an inaccurate conclusion.
Review the complete report and confirm dating and fetus number. Further testing is based on the combined risk or ultrasound findings, not on an isolated high E3.
What Low estriol Results Can Mean
Low E3 may reflect a benign explanation such as incorrect dating, but very low values can signal fetal or placental conditions that deserve specialist review.
- Pregnancy dated later than the true gestational age.
- Trisomy 18 or trisomy 21 within a characteristic multi-marker pattern.
- Fetal demise or severe placental dysfunction.
- Fetal adrenal hypoplasia or impaired precursor production.
- Steroid sulfatase deficiency, which can cause X-linked ichthyosis.
- Smith-Lemli-Opitz syndrome or other rare steroid-synthesis disorders.
A low uE3 screen does not identify which cause is present. First steps include verifying gestational age, reviewing all serum markers, and performing or reviewing ultrasound. Genetic counseling can explain cell-free DNA screening and diagnostic testing, including what each can and cannot answer.
Persistently very low uE3 with otherwise unusual findings may prompt targeted testing for steroid sulfatase deficiency or other rare disorders. These decisions are specialist-led because prevalence is low and the consequences of false interpretation are substantial.
Do not make pregnancy decisions from the E3 value alone. Ask for the numerical risk, the program cutoff, the ultrasound findings, and the available confirmatory options.
How Results Fit With Other Hormones and Tests
Prenatal screening depends on marker patterns rather than a single hormone.
| E3 finding | Other information | Interpretive direction |
|---|---|---|
| Low uE3 | Combined screen risk elevated | Offer counseling and screening/diagnostic options |
| Low uE3 | Dating uncertain | Confirm gestational age before concluding risk |
| Very low uE3 | Normal or unusual ultrasound | Consider rare fetal steroid disorders with specialists |
| High uE3 | Multiple gestation or later dating | Recalculate with correct pregnancy data |
| Any E3 value | Concerning ultrasound finding | Ultrasound finding may drive diagnostic evaluation |
Cell-free DNA is a highly sensitive screening test for common trisomies but does not replace diagnostic testing and does not screen for every condition associated with very low uE3. Amniocentesis can provide diagnostic genetic information but is invasive and requires counseling.
Next Steps After the Result
Follow-up should place the E3 value back into the complete prenatal screen and confirm that the pregnancy information used by the laboratory is accurate.
- Review the complete serum-screen report, not only the uE3 line.
- Confirm gestational age, fetal number, maternal data, and IVF or donor-egg details.
- Arrange or review a detailed ultrasound.
- Discuss cell-free DNA screening and diagnostic testing with an obstetric or genetic professional.
- Consider targeted evaluation for very low uE3 when common explanations are excluded.
- Continue pregnancy monitoring based on the full obstetric picture.
A screen-positive result can be emotionally difficult. Genetic counseling should explain the absolute probability, the false-positive rate, and the difference between additional screening and diagnosis. Declining further testing is also a valid informed choice when the options and uncertainties are understood.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
Contact obstetric care urgently for vaginal bleeding, severe abdominal pain, severe headache, visual symptoms, sudden swelling, reduced fetal movement after movement is established, fluid leakage, or contractions. These symptoms require clinical assessment regardless of E3.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
Fertility decisions should not be reduced to a single endocrine value. A hormone may help choose medication dose, confirm ovulation, or identify a treatable disorder, but it does not measure every step required for pregnancy. Reproductive age, sperm exposure or semen quality, tubal patency, uterine anatomy, timing, prior pregnancies, and the duration of trying all influence the next step. A balanced evaluation prevents overreaction to an incidental result.
Testing can be different during pregnancy, adolescence, menopause, or hormone treatment because physiology is intentionally changing. A range derived from untreated adults may be inappropriate in these settings. Ask whether the laboratory interval matches the patient’s age and reproductive state and whether the clinical team uses a separate treatment or pregnancy target. This is particularly important when a portal automatically marks a result high or low against a generic range.
A laboratory method with greater analytical specificity is useful when the expected concentration is low, the result is surprising, or a major decision depends on the number. Mass-spectrometry methods can separate closely related steroids better than many immunoassays, while dynamic tests can reveal reserve or responsiveness that a basal sample cannot show. The best method depends on the hormone and question; a technically sophisticated test is not automatically necessary for every routine result.
References
- Screening for Fetal Chromosomal Abnormalities 2026 (Practice Advisory)
- The role of placental hormones and metabolites in modulating maternal adaptations to pregnancy 2025 (Review)
- Estrogen Actions in Placental Vascular Morphogenesis and Remodeling 2023 (Review)
- The pathophysiological role of estrogens in the initial stages of pregnancy: molecular mechanisms and clinical implications 2023 (Review)
- The association of maternal serum biomarkers and birth weight in twin pregnancy: a retrospective cohort study 2022 (Study)
Disclaimer
This article is general prenatal-testing information and cannot interpret an individual pregnancy screen. An abnormal uE3 result is not a diagnosis. Review results promptly with the obstetric team or a genetic counselor, especially when ultrasound or other markers are abnormal.
